Australian research has found that contrary to some previous reports, a history of smoking does not reduce the efficacy of immune checkpoint inhibitors in people with lung cancer. Some study-level meta-analyses have suggested that never smokers with non-small cell lung cancer (NSCLC) may obtain less effect from ICIs than previous or current smokers, a finding ...
Smoking status does not reduce immunotherapy efficacy in lung cancer
By Michael Woodhead
7 Dec 2021